© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
August 12, 2022
The panel closes their discussion on myelofibrosis treatment updates by sharing clinical pearls for community oncologists.
Experts delve into the unmet needs in the myelofibrosis treatment landscape and highlight promising ongoing clinical trials.
July 29, 2022
A look at sequencing strategies for myelofibrosis treatments.
Dr Srdan Verstovsek shares how he assesses myelofibrosis treatment response in his clinical practice.
July 22, 2022
Raajit Rampal, MD, explains how he considers safety profiles when deciding on appropriate treatment for myelofibrosis and how he manages toxicities for patients.
A discussion on when to switch a patient with myelofibrosis to a new JAK inhibitor treatment, and possible strategies for transitioning.
July 15, 2022
John Mascarenhas, MD, presents a clinical scenario of a 73-year-old man with myelofibrosis and a low platelet count.
A panel of experts considers treatment options for patients with myelofibrosis based on platelet counts, while factoring in health insurance barriers.
July 07, 2022
Raajit Rampal, MD, PhD, shares the treatment options he would consider for the presented clinical scenario.
A review of the approved treatments for myelofibrosis, including dosing guidelines and supporting clinical trial data.